2015 Towards an HIV Cure Symposium
18 & 19 July 2015

Poster Exhibition

Reverse transcription and integration

PE1: Primary resistance against dolutegravir decreases HIV integration
Thibault Mesplède
McGill University AIDS Centre, Lady Davis Institute for Medical Research – Jewish General Hospital, Canada


PE2: HIV-1 integrase variants retarget proviral integration and are associated with disease progression
Rik Gijsbers
KU Leuven University, Belgium


Intrinsic cellular defences and restriction factors

PE3: HIV-1 Vpu exploits the crosstalk between BST2 and the ILT7 receptor to
inhibit innate sensing of infected T-cells by plasmacytoid dendritic cells
Éric A. Cohen
Institut de Recherches Cliniques de Montréal & Université de Montréal, Canada


PE4: Decreased interferon signature in HIV-1 viremic controllers
Rui Andre Raposo
George Washington University, United States


PE5: Differential effects of cell-surface CD4 and tetherin on ADCC mediated by
non-neutralizing and broadly neutralizing anti-HIV antibodies: the role of Nef
and Vpu
Tram Ngoc Quynh Pham
Institut de Recherches Cliniques de Montréal, Canada


Type I Interferons (viral inhibition, immunomodulatory functions)

PE6: Comparison of gene expression profile between human and macaque
dendritic cells infected with virus carrying or not Vpx-loaded particles and
assessment of their pathogenic impact
Esther Calonge
Centro Nacional Microbiologia, ISCII, Spain


Viral mechanisms of HIV/SIV persistence and latency

PE7: Low frequency of HIV rebound after antiretroviral treatment interruption
Miles Davenport
UNSW Australia, Australia


PE8: Purging HIV-1 from latent reservoirs using human methyltransferase inhibitors
Sadia Samer
Federal University of Sao Paulo, Brazil


Host cellular factors and latency

PE9: Transcriptional profiling identifies RORC and PPARG as two major mechanisms regulating HIV permissiveness in primary Th17 cells
Yuwei Zhang
CHUM Research Centre, Université de Montréal, Canada


Cellular and tissue reservoirs of HIV/SIV

PE10: Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T-cells
Salma Jaafoura
INSERM U 1012, France


PE11: Quantification and replication competency of HIV-1 following latency disruption in CD4+ T-cells
Jason Hataye
National Institute of Allergy and Infectious Disease, Vaccine Research Centre, United States


PE12: T-cell immunity in testicular tissue of ART-treated HIV-infected subjects: results from the Orchid study
Mohammad-Ali Jenabian
Université du Québec á Montréal (UQAM), Canada


PE13: Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages
Francesca Graziano
San Raffaele Scientific Institute, San Raffaele University, Milan/p>


Measurement of HIV/SIV reservoirs

PE14: Defining the Unique biomarkers of latently infected T-cells
Mudit Tyagi
George Washington University, United States


PE15: Flow-based differentiation between latently HIV-1-infected single cells expressing Gag mRNA alone or in conjunction with Gag protein following latency reversal
Gloria Martrus
Heinrich-Pette-Institut Leibniz Institute for Experimental Virology, Germany


PE16: HIV-1 transcription is stable during frequent longitudinal sampling in aviremic patients on ART: implications for HIV cure research
Steffen Leth
Aarhus University Hospital, Denmark


PE17: Anti-HIV antibody responses reflect the quantifiable HIV reservoir size
Sulggi Lee
University of California, San Francisco, United States


PE18:  Improved assays to measure the inducible latent HIV reservoir
Marta Massanella
UCSD, United States


PE19 LB:  Time associated changes in cell-associated HIV RNA in HIV-infected subjects on suppressive antiretroviral therapy - implications for clinical trials of cure interventions
Christina Chang
The University of Melbourne & Alfred Hospital, Australia


PE20 LB:  Assay to measure the latent reservoir of replication-competent HIV-1 in suppressed patients based on ultra deep sequencing
Sook-Kyung Lee
University of North Carolina, United States


HIV-1 controllers (including post-treatment controllers)

PE21: Profound alterations in cholesterol metabolism restrict HIV-1 trans infection of CD4 T-cells in nonprogressors
Giovanna Rappocciolo
University of Pittsburgh, United States


Asymptomatic long term non-progression

PE22: Characterization of anti-gp41 antibodies eliciting viral neutralization and protecting against CD4 depletion in long-term non-progressors
Patrice Debré
CIMI-Paris, INSERM U 1135, France


PE23: CD40L-induced tunneling nanotube networks facilitate proinflammatory dendritic cell-mediated HIV-1 trans-infection of CD4+ T-cells
Colleen Zaccard
University of Pittsburgh, United States


Targeting HIV persistence during ART (cure strategies)

PE24: MG1 and VSVΔ51 viruses target and kill latently HIV-infected myeloid cells
Nischal Ranganath
University of Ottowa, Canada


PE25: Minimal HIV-1 Gag epitope presentation in a T-cell line during reactivation
Xiaomei Tallie Kuang
Simon Fraser University, Canada


PE26: Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle efficiently limits viral reactivation and halts viral replication
Monique Nijhuis
University Medical Center Utrecht, Netherlands


PE27: Anti-HIV CAR+ lymphocytes protected from HIV-infection by CCR5 disruption as a strategy to cure HIV
Thor Wagner
University of Washington & Seattle Children’s Research Institute, United States


PE28:  Universal Tre-recombinase (uTre) specifically targets the majority of primary HIV-1 isolates
Joachim Hauber
Heinrich Pette Institute & German Center for Infection Research (DZIF), Germany


PE29:  Polyvalent immune responses correlate with lower number of HIV infected CD4 T-cells in chronically infected subjects treated with autologous RNA pulsed DC therapy
Irina Tcherepanova
Argos Therapeutics Inc., United States


PE30:  HIV rebound and meningoencephalitis following ART interruption after allogeneic hematopoietic stem cell transplant: an investigation of the source of HIV rebound
Adam Capoferri
Howard Hughes Medical Institute & Johns Hopkins University, United States


PE31: Robust HIV-specific T-cells in post-treatment controllers from the VISCONTI cohort
Brigitte Autran
Université Pierre et Marie Curie, Sorbonne Universités & Pitié-Salpétrière, C. Foix University Hospital, AP-HP, France


PE32: Nef inhibition for enhanced NK cell killing of cells expressing reactivated HIV-1
Eileen Scully
Ragon Institute of MGH, MIT and Harvard, Brigham & Women’s Hospital, United States


PE33:  HIV-specific latency reversing therapies that exploit novel pathways for suboptimal Tat protein expression
Damian Purcell
University of Melbourne, Australia


PE34:  Type-1 programmed dendritic cells induce primary CTL capable of effectively targeting the HIV-1 reservoir
Robbie B. Mailiiard
University of Pittsburgh, United States


PE35:  Predictive pharmacodynamics model of transgene delivery for curative HIV gene therapy
Pavitra Roychoudhury
Fred Hutchinson Cancer Research Center, United States


PE36 LB: Novel activators of latent HIV-1 from natural products
Ian Tietjen
Simon Fraser University & University of British Colombia, Canada


PE37 LB: Protective HLA alleles fail to predict immune control of HIV after ART interruption in chronically infected patients with low HIV-DNA from the ULTRASTOP Study
Chiraz Hamimi
Sorbonne Universités & INSERM, UMR-S 1135, France


PE38 LB: Reversal of HIV-1 latency by activation of patient-derived CD4+T-cells results in clonal expansion and sustained production of infectious virus from a subset of cells
John Bui
University of Pittsburgh & Howard Hughes Medical Institute, United States


Novel approaches in immunotherapeutics (including bnAbs and anti-inflammatory mediators)

PE39: Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitope
Kazuki Tanaka
Matsushita Project Laboratory, Japan


PE40: A novel TLR-9 agonist (MGN1703) activates NK-cells and enhances NK-cell mediated viral killing of HIV-1 infected CD4+ T-cells ex vivo
Rasmus Offersen
Aarhus University Hospital, Denmark


PE41: Treatment with anti-α4β7 integrin antibody reduces virus-mediated gastrointestinal pathology by targeting distinct mucosal tissues
Siddappa Byrareddy
Emory University, United States


PE42 LB: Novel CD4-based bispecific chimeric antigen receptors provide potent and targeted killing of HIV-infected cells: a potential functional cure strategy
Barna Dey
National Institutes of Health, United States


Therapeutic vaccines

PE43: Monocyte-derived DC electroporated with mRNAs encoding both specific HIV antigens and DC adjuvants are able to improve T-cell functionality
Felipe García
Hospital Clinic, IDIBAPS, University of Barcelona, Spain


PE44: Therapeutic conserved elements (CE) DNA vaccine increases T-cell responses against highly conserved viral sequences in the setting of pre-existing immunodominant responses induced by chronic viral infection
Paul Munson
University of Washington, United States


PE45: Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys
Ma Luo
National Microbiology Laboratory & University of Manitoba, Canada


PE46: Safety and immunogenicity of ChAd.HIVconsv and MVA.HIVconsv therapeutic vaccines in a cohort of early treated HIV-1 infected individuals
Beatriz Mothe
IrsiCaixa AIDS Research Institute – HIVACAT, Fundació Lluita contra la Sida & UVic-UCC, Spain


PE47: Development of a latency reversing activator vaccine (ACT-VEC) platform for HIV-1 cure therapy
Jamie F. S. Mann
University of Western Ontario, Canada


PE48: Broadly specific, cytolytic T cell responses and lower inflammatory responses correlate with durable viral remission following therapuetic DNA vaccination in SIV-infected macaques
Deborah Fuller
University of Washington & Washington National Primate Research Center, United States


Novel animal/virus models for vaccine, cure research, and inhibitor development

PE49: Crispr/Cas9 gene editing eradicates latent and protects cells against new HIV-1 infection
Kamel Khalili
Temple University, United States


Acute and early infection

PE50: High rates of non-reactive HIV serology after antiretroviral treatment initiated in acute HIV infection
James L. K. Fletcher
SEARCH, The Thai Red Cross AIDS Research Centre, Thailand


PE51 LB: Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to reducing CD8 T-cell elevation: Relevance for clinical outcome
Wei Cao
McGill University Health Center, United States & Peking Union Medical College Hospital, China


PE52 LB: HIV reservoirs in semen at the time of Primary infection
Antoine Chéret
Bicêtre Hospital, AP-HP & Paris Descartes University, France


PE53 LB: CD4/CD8 ratio at ART initiation as a predictor of viral rebound following interruption of ART initiated in primary HIV infection
John Thornhill
Imperial College London, United Kingdom


Long-term non-progressors and elite controllers

PE54: Ultrastop: Is remission achievable in HIV-1 patients with low HIV DNA reservoir?
Christine Katlama
AP-HP Department of Infectious Diseases, Pitié-Salpêtrière University Hospital, Sorbonne Universités & INSERM, UMR_S 1136, France


Timing of therapy initiation

PE55: Initiation of Antiretroviral Therapy at high CD4 cell counts is associated with Increased Adherence, Viral Suppression, and Decreased HIV Drug Resistance in British Columbia, Canada
Viviane D. Lima
British Colombia Centre for Excellence in HIV/AIDS, Canada


PE56: Long-term early antiretroviral therapy limits the HIV-1 reservoir size as compared to later treatment initiation but not to levels found in long-term non-progressors
Eva Malatinkova
Ghent University and University Hospital Ghent, Belgium


Ethical issues in clinical trials and treatment strategies

PE57: Proposed HIV cure research in South Africa: perspectives of HIV researchers, clinicians and advocates on the anticipated ethical challenges
Keymanthri Moodley
Stellenbosch University, Centre for Medical Ethics and Law, South Africa


PE58: The ethics of HIV cure clinical research among acutely infected adults: points for consideration
Adam Lloyd Gilbertson
University of North Carolina at Chapel Hill, United States & University of Oxford, United Kingdom


Therapeutic vaccine trials

PE59: HIV-1 reservoir dynamics after vaccination and antiretroviral therapy interruption are driven by dendritic cell-vaccine induced T-cell responses
Felipe García
Hospital Clinic, IDIBAPS, University of Barcelona, Spain


PE60: Patient-reported receptiveness to a HIV therapeutic vaccine
David Zucman
Centro Medico Chirurgical Foch, France


PE61: Vacc-4x/lenalidomide increases naïve CD4 T-cells in well controlled patients on ART with low preART CD4 counts and poor immune reconstitution
Jan van Lunzen
University Medical Center Hamburg-Eppendorf, Germany


PE62 LB: A first-in-human phase I/II trial demonstrates the safety and the immunogenicity of a lentiviralbased therapeutic HIV vaccine eliciting potent polyfunctional multispecific CD8 and CD4 Tcell responses in HIV-infected individuals
Hélène Toussaint
Theravectys, France


Complementary and traditional medicines

PE63: “Hard” versus “Soft” HIV Cure: an Anthropological investigation of the
Cultural Meaning of HIV Cure in China
Qingyan Ma
University of North Carolina Project-China & Guangzhou No. Eight People’s Hospital China


Curative interventions (including those aimed at reservoir depletion)

PE64: Reduction in total HIV-1 proviral DNA following re-boost immunizations using the peptide-based therapeutic vaccine candidate, Vacc-4x, during ART
Maja A. Sommerfelt
Bionor Pharma ASA, Norway


PE65: Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-infected individuals
Ayla Cash
Johns Hopkins University, United States


Novel therapeutic approaches (including gene therapy)

PE66: VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. Phase II initial analysis of the IPROTECT1 multicenter European study
Christine Katlama
AP-HP Pitie Salperiere Hospital & INSERM, France


PE67 LB: VAC-3S, a safe Immunotherapeutic HIV Vaccine decreased total HIV DNA and increased CD4/CD8 ratio: Phase I Final Results
Raphaël Ho Tsong Fang
InnaVirVax, France


PE68 LB: Perspectives on the acceptability of HCRC trials: the challenges for physicians and PLWHIV (ANRS APSEC)
Bruno Spire
INSERM U912 SESSTIM, Aix Marseille Université & ORS PACA, France


Clinical trials and antiretroviral therapy in children and adolescents

PE69 LB: Low but Detectable IFN-γ Responses against Clade-Matched HIV-1 Peptides in Early-Treated Vertically-Infected Children with Long-Term Sustained Viral Suppression
Hinatea Dieumegard
Centre de recherché du CHU Saint-Justine & Université de Montréal, Canada


Engagement of community in service delivery

PE70: Results of a community needs assessment and pilot test of a novel HIV cure research training curriculum
Karine Dubé
UNC-Chapel Hill, Collaboratory of AIDS Researchers for Eradication (CARE), United States


PE71: Bringing community to cure
Laurie Sylla
Fred Hutchinson Cancer Research Center, defeatHIV Martin Delaney Collaboratory Community Advisory Board, United States


PE72: Planning and Community Engagement for HIV Cure Research in Canada, A Collaborative Program Between National Research Teams and Key Populations
Robert Reinhard
Institut de Recherches Cliniques de Montréal & Ontario HIV Treatment Network, Canada


PE73: The transition from incurable to curable: Pediatric leukemia, psychological dimensions of new disease cures, and implications for HIV
Catherine Gliwa
University of California Los Angeles & University of North Carolina at Chapel Hill, United States


PE74 LB: HIV cure goes viral: an analysis of HIV cure #hashtags
Kathryn Muessig
University of North Carolina at Chapel Hill, Gillings School of Global Public Health, United States

 

With the support of: